FDA Approves New Nilotinib Formulation for CML Treatment

The FDA has granted approval for an orally disintegrating tablet version of nilotinib, branded as Cavhanza, for specific adult patients with Philadelphia chromosome-positive chronic myeloid leukemia. This innovative formulation aims to simplify treatment by allowing co-administration with acid-reducing medications without timing concerns. The approval represents an advancement in managing CML, potentially improving patient adherence and convenience.